JP2020502106A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502106A5 JP2020502106A5 JP2019531623A JP2019531623A JP2020502106A5 JP 2020502106 A5 JP2020502106 A5 JP 2020502106A5 JP 2019531623 A JP2019531623 A JP 2019531623A JP 2019531623 A JP2019531623 A JP 2019531623A JP 2020502106 A5 JP2020502106 A5 JP 2020502106A5
- Authority
- JP
- Japan
- Prior art keywords
- bipolar disorder
- pharmaceutical composition
- formula
- group
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170224 | 2016-12-14 | ||
| KR10-2016-0170224 | 2016-12-14 | ||
| PCT/KR2017/014740 WO2018111008A1 (ko) | 2016-12-14 | 2017-12-14 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502106A JP2020502106A (ja) | 2020-01-23 |
| JP2020502106A5 true JP2020502106A5 (OSRAM) | 2021-01-14 |
| JP7208139B2 JP7208139B2 (ja) | 2023-01-18 |
Family
ID=62559442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531623A Active JP7208139B2 (ja) | 2016-12-14 | 2017-12-14 | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11571410B2 (OSRAM) |
| EP (1) | EP3556366B1 (OSRAM) |
| JP (1) | JP7208139B2 (OSRAM) |
| KR (1) | KR102635938B1 (OSRAM) |
| CN (1) | CN110290788A (OSRAM) |
| AU (1) | AU2017374458B2 (OSRAM) |
| BR (1) | BR112019011930A2 (OSRAM) |
| CL (1) | CL2019001618A1 (OSRAM) |
| IL (1) | IL267195B2 (OSRAM) |
| MX (1) | MX2019006940A (OSRAM) |
| MY (1) | MY199104A (OSRAM) |
| WO (1) | WO2018111008A1 (OSRAM) |
| ZA (1) | ZA201903747B (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3854391B1 (en) * | 2018-09-21 | 2024-03-13 | SK Biopharmaceuticals Co., Ltd. | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| WO2020060252A1 (ko) * | 2018-09-21 | 2020-03-26 | 에스케이바이오팜 주식회사 | 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도 |
| AU2020389425A1 (en) * | 2019-11-22 | 2022-06-02 | Sk Biopharmaceuticals Co., Ltd. | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU6100A (sh) * | 1997-08-14 | 2002-10-18 | F.Hoffmann-La Roche Ag. | Heterociklični viniletri protiv neuroloških poremećaja |
| CZ2004266A3 (cs) * | 2000-07-21 | 2005-02-16 | Teva Pharmaceutical Industries, Ltd. | Použití derivátů amidů kyseliny valproové a kyseliny 2-valproenové pro léčbu mánie při bipolární poruše |
| ATE324108T1 (de) * | 2001-02-27 | 2006-05-15 | Ortho Mcneil Pharm Inc | Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung |
| US7122576B2 (en) * | 2001-02-27 | 2006-10-17 | Plata-Salaman Carlos R | Carbamate compounds for use in preventing or treating bipolar disorder |
| EA200701065A1 (ru) | 2004-11-16 | 2007-12-28 | Элан Фарма Интернэшнл Лтд. | Инъецируемые составы, содержащие нанодисперсный оланзапин |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US20080103199A1 (en) * | 2006-10-31 | 2008-05-01 | Haas Magali | Treatment of pervasive developmental disorders |
| BRPI0924997B1 (pt) | 2009-06-22 | 2024-01-16 | Sk Biopharmaceuticals Co., Ltd | Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US9610274B2 (en) * | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9981950B2 (en) | 2014-08-15 | 2018-05-29 | Janssen Pharmaceuticals, Inc. | Triazoles as NR2B receptor inhibitors |
-
2017
- 2017-12-14 EP EP17881161.8A patent/EP3556366B1/en active Active
- 2017-12-14 AU AU2017374458A patent/AU2017374458B2/en active Active
- 2017-12-14 MY MYPI2019003348A patent/MY199104A/en unknown
- 2017-12-14 IL IL267195A patent/IL267195B2/en unknown
- 2017-12-14 US US16/468,782 patent/US11571410B2/en active Active
- 2017-12-14 WO PCT/KR2017/014740 patent/WO2018111008A1/ko not_active Ceased
- 2017-12-14 CN CN201780077574.0A patent/CN110290788A/zh active Pending
- 2017-12-14 MX MX2019006940A patent/MX2019006940A/es unknown
- 2017-12-14 JP JP2019531623A patent/JP7208139B2/ja active Active
- 2017-12-14 KR KR1020197018408A patent/KR102635938B1/ko active Active
- 2017-12-14 BR BR112019011930-2A patent/BR112019011930A2/pt unknown
-
2019
- 2019-06-11 ZA ZA2019/03747A patent/ZA201903747B/en unknown
- 2019-06-12 CL CL2019001618A patent/CL2019001618A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512531A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JP2016518437A5 (OSRAM) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2017527532A5 (OSRAM) | ||
| JP2015532295A5 (OSRAM) | ||
| JP2009541223A5 (OSRAM) | ||
| JP2017511360A5 (OSRAM) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2014511891A5 (OSRAM) | ||
| JP2018517686A5 (OSRAM) | ||
| JP2015511609A5 (OSRAM) | ||
| JP2019516739A5 (OSRAM) | ||
| JP2016503797A5 (OSRAM) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2015504081A5 (OSRAM) | ||
| JP2019505529A5 (OSRAM) | ||
| JP2019535723A5 (OSRAM) | ||
| RU2018113718A (ru) | Новые соединения | |
| JP2019520344A5 (OSRAM) | ||
| JP2011509302A5 (OSRAM) | ||
| JP2020502106A5 (OSRAM) | ||
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| JP2011518168A5 (OSRAM) | ||
| JP2019516726A5 (OSRAM) |